The world is talking about ending AIDS. AVAC’s advocacy is dedicated to realizing that vision. To get there we must:
In the second installment of AVAC’s webinar series on COVID-19 and its relationship to HIV, Dr. Mark Feinberg, CEO of IAVI, will share experiences and lessons from Ebola and HIV vaccine development that might be applied to COVID-19 vaccine development. Dr. Feinberg will also describe the history and role of the Coalition for Epidemic Preparedness Innovations (CEPI), which supports vaccine development against emerging infectious diseases, including COVID-19.
The latest installment of AVAC’s podcast, Px Pulse, is up. In this episode, AVAC puts a spotlight on HVTN 702, or Uhambo, one of the most anticipated HIV vaccine efficacy trials in the field. Data show the vaccine tested is safe, but vaccinations were stopped early after a scheduled review showed it did not offer protection.
As many of you may have heard, the recent Conference on Retroviruses and Opportunistic Infections (CROI) was held as a a virtual meeting. The CROI organizers updated their site with additional details and opportunities to participate virtually and relive sessions at a later date.
Help us collect examples and evidence that supports differentiated service delivery (DSD) models for PrEP—fill out this survey!
AVAC has an extensive online resource library with hundreds of Reports, Publications, Infographics & more. And it includes powerful search features to find exactly what you’re looking for.
AVAC uses education, policy analysis, advocacy, community mobilization and a network of global collaborations to accelerate ethical development and global delivery of biomedical HIV prevention options. Read more
AVAC advocates for a comprehensive response to the epidemic, involving smart use of every proven HIV prevention option available today and sustained research into many new strategies.